
Dr. Joseph Biederman, Professor of Psychiatry
Harvard University, Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD,
Massachusetts General Hospital (Photo: MGH)
The most detailed and knowledgeable assessment comes from journalist Alison Bass, a muckraking investigative reporter and author who writes on financial shenanigans within the pharmaceutical industry. Bass calls Harvard’s sanctions “essentially a slap on the wrist.” Here’s her full take:
In 2008, Congressional investigators accused the three psychiatrists — Biederman, Thomas Spencer and Timothy Wilens — of failing to disclose more than $1 million each in payments from the drug industry. As I blogged about here, most of Biederman’s financial ties were with the makers of anti-psychotic drugs at the very same time he was promoting the use of these drugs in the treatment of childhood bipolar disorder. According to documents released in a lawsuit, Biederman also courted funding from Johnson & Johnson by promising that his work at Mass. General would promote the use of its anti-psychotic Risperdal in children. Johnson & Johnson gave the hospital $700,000 for a Biederman-led research center that did studies promoting Risperdal. All of which raises the question of whether Biederman helped the drug company illegally market the off-label use of its anti-psychotic drug in children
But rather than suspend or fire him for such unethical and possibly criminal behavior, Harvard and Mass. General let him and his two colleagues off easy. According to The Boston Globe, they required the three physicians to refrain from all paid industry-sponsored activities for one year and undergo unspecified additional training. A letter Biederman and his colleagues wrote to co-workers about the remedial actions also mentioned that they might “suffer a delay of consideration for promotion and advancement.” Continue reading




